We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+3.32%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.3B
AUM Growth
+$177M
Cap. Flow
+$235M
Cap. Flow %
18.05%
Top 10 Hldgs %
40.67%
Holding
213
New
103
Increased
34
Reduced
21
Closed
43

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$47.9M
2
ABBV icon
AbbVie
ABBV
+$27.8M
3
JNJ icon
Johnson & Johnson
JNJ
+$18.7M
4
LPSN icon
LivePerson
LPSN
+$16.1M
5
AZN icon
AstraZeneca
AZN
+$13.6M

Top Sells

Rank Stock Value
1
NVS icon
Novartis
NVS
+$40.5M
2
BMY icon
Bristol-Myers Squibb
BMY
+$26.4M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$12.8M
4
ZYME icon
Zymeworks
ZYME
+$11.6M
5
META icon
Meta Platforms (Facebook)
META
+$10.9M

Sector Composition

Rank Sector Weight
1 Healthcare 62.55%
2 Technology 7.69%
3 Industrials 4.91%
4 Financials 2.93%
5 Consumer Discretionary 1.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MREO
76
Mereo BioPharma
MREO
$54.7M
$4.42M 0.34%
+1,312,415
New +$4.64M
CLOU icon
77
PUT
Global X Cloud Computing ETF
CLOU
$240M
$4.39M 0.34%
+170,600
New +$4.69M
CRNX icon
78
Crinetics Pharmaceuticals
CRNX
$8.84B
$4.34M 0.33%
+284,224
New +$4.41M
FTCH
79
DELISTED
Farfetch Limited Class A Ordinary Shares
FTCH
$4.24M 0.33%
+80,000
New +$4.89M
ORIC icon
80
Oric Pharmaceuticals
ORIC
$1.15B
$4.16M 0.32%
169,900
-12,300
-7% -$389K
FOREU
81
DELISTED
Foresight Acquisition Corp. Units
FOREU
$4.16M 0.32%
+420,000
New +$4.25M
STTK icon
82
Shattuck Labs
STTK
$675M
$4.11M 0.32%
140,665
+85,365
+154% +$3.59M
ARKO icon
83
ARKO Corp
ARKO
$896M
$4.06M 0.31%
408,000
-192,000
-32% -$1.79M
HCCCU
84
DELISTED
Healthcare Capital Corp. Unit
HCCCU
$3.95M 0.3%
+400,000
New +$4.09M
IFRX icon
85
InflaRx
IFRX
$250M
$3.9M 0.3%
+1,000,000
New +$5.12M
KA
86
DELISTED
Kineta, Inc. Common Stock
KA
$3.78M 0.29%
29,801
+11,168
+60% +$1.51M
ATXS
87
DELISTED
Astria Therapeutics
ATXS
$3.74M 0.29%
+215,667
New +$3.9M
BGMS
88
Bio Green Med Solution Inc
BGMS
$4.91M
$3.61M 0.28%
+141
New +$3.97M
NKTX icon
89
Nkarta
NKTX
$150M
$3.32M 0.25%
+101,006
New +$4.83M
GRCL
90
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$3.27M 0.25%
+212,600
New +$5.02M
EWTX icon
91
Edgewise Therapeutics
EWTX
$4.13B
$3.25M 0.25%
+100,000
New +$3.24M
LVTX
92
DELISTED
LAVA Therapeutics
LVTX
$3.25M 0.25%
+213,894
New +$2.94M
LGV.U
93
DELISTED
Longview Acquisition Corp. II Units, each consisting of one share of Class A Common Stock and one-fifth of one redeemable Warrant
LGV.U
$3.01M 0.23%
+300,000
New +$3.01M
EUCR
94
DELISTED
Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
$3.01M 0.23%
+304,025
New +$3.12M
CLRMU
95
DELISTED
Clarim Acquisition Corp. Unit
CLRMU
$2.98M 0.23%
+300,000
New +$3.06M
GRTX
96
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$2.85M 0.22%
323,348
-144,314
-31% -$1.58M
DMRA
97
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.78B
$2.72M 0.21%
17,921
+2,250
+14% +$612K
NBP
98
NovaBridge Biosciences American Depositary Shares
NBP
$185M
$2.66M 0.2%
54,962
-126,858
-70% -$6.88M
PHAS
99
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$2.6M 0.2%
+750,000
New +$3.04M
ARGX icon
100
argenx
ARGX
$53.4B
$2.55M 0.2%
9,249
– –
2 3
4
5 6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2021 Portfolio in Review

As of Q1 2021, Sphera Funds Management held 213 positions worth $1.3B, up 16% from $1.13B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Sphera Funds Management deployed $235M of net new capital in Q1 2021, opening 103 new positions and adding to 34 existing holdings. Its largest new stake was Sanofi: 997,900 shares worth $49.4M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 68% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $26.4M trimmed.

  • Sphera Funds Management's largest Q1 2021 buy was Sanofi: 997,900 shares worth $49.4M.
  • Sphera Funds Management added most to AbbVie in Q1 2021, an estimated $27.8M increase.
  • Sphera Funds Management's biggest Q1 2021 reduction was Bristol-Myers Squibb, cutting an estimated $26.4M.
  • Sphera Funds Management fully exited Novartis in Q1 2021, selling an estimated $40.5M.
  • Sphera Funds Management's ten largest holdings make up 41% of its $1.3B portfolio in Q1 2021.
  • Sphera Funds Management opened 103 new positions and closed 43 in Q1 2021.
  • Sphera Funds Management's portfolio value rose 16% quarter-over-quarter to $1.3B.

Based on Sphera Funds Management's 13F filing for Q1 2021, filed 17 May 2021.